Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer. Displaying page 38 of 41.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next»
    EudraCT Number: 2019-004332-36 Sponsor Protocol Number: DTX-SPL8783-002 Start Date*: 2020-02-01
    Sponsor Name:Starpharma Pty Ltd
    Full Title: A Phase 1/2 Modular, Multi-Arm Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of DTX-SPL8783 (DEP docetaxel/DEP-DTX) in Combination with Anti-Cancer Treatments, in Patients wit...
    Medical condition: Advanced malignant solid tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005546-63 Sponsor Protocol Number: DOTATER1_26_15 Start Date*: 2016-05-30
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA
    Full Title: Peptide receptor radionuclide therapy in tumors with high expression of somatostatine receptors.
    Medical condition: Cancer patients with high expression of somatostatin receptors (neurendocrine tumors, thyroid tumors, lung tumors, meningiomas).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000776-19 Sponsor Protocol Number: D926UC00001 Start Date*: 2022-11-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients wi...
    Medical condition: Various Advanced/Metastatic solid tumour types - Endometrial Cancer - Gastric Cancer - Ovarian Cancer - Metastatic castration-resistant prostate cancer - Colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007129 Cancer-related morbidities HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003342-25 Sponsor Protocol Number: P170604J Start Date*: 2018-09-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Long-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis
    Medical condition: Patients with breast, prostate, and colorectal active cancer, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after 6 months of an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076654 Cancer-associated thrombosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) AT (Ongoing) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004952-14 Sponsor Protocol Number: 0209-01 Start Date*: 2021-07-07
    Sponsor Name:Constellation Pharmaceuticals, Inc.
    Full Title: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Tumors
    Medical condition: advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, ovarian clear cell cancer, endometrial carcinoma, GCB-DLBCL, small cell lu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2010-021613-23 Sponsor Protocol Number: Start Date*: 2010-11-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: HYPAZ: An open-label investigation into hypertension induced by pazopanib therapy
    Medical condition: Hypertension induced by pazopanib treatment of various cancer types
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004558-24 Sponsor Protocol Number: CC-115-ST-001 Start Date*: 2012-06-29
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINIS...
    Medical condition: Subjects with advanced solid tumors, non-hodgkin lymphoma (NHL) and multiple myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000148-23 Sponsor Protocol Number: FAPI-PET-Trial Start Date*: 2021-06-30
    Sponsor Name:University Hospital Essen
    Full Title: 68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical Trial
    Medical condition: Patients receiving 68Ga-FAPI-46 PET both at initial diagnosis and restaging before treatment decisions
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002152-26 Sponsor Protocol Number: ISRCTN86894066 Start Date*: 2009-01-20
    Sponsor Name:The Royal Marsden Foundation Trust and The Institute of Cancer Research
    Full Title: Randomised double-blind controlled phase III trial of hyperbaric oxygen therapy in patients suffering long-term adverse effects of radiotherapy for pelvic cancer
    Medical condition: Chronic radiation-induced gastrointestinal symptoms
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10057480 Hyperbaric oxygen therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004727-37 Sponsor Protocol Number: CAAA603A12101 Start Date*: 2019-02-18
    Sponsor Name:Advanced Accelerator Applications International SA
    Full Title: A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with...
    Medical condition: Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Completed) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002688-77 Sponsor Protocol Number: D9720C00001 Start Date*: 2021-06-15
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and...
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005181-31 Sponsor Protocol Number: A4091003 Start Date*: 2009-04-29
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES
    Medical condition: PAIN DUE TO BONE METASTASES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) SK (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000416-21 Sponsor Protocol Number: CA030-001 Start Date*: 2019-01-31
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) DE (Completed) PL (Completed) FI (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002552-16 Sponsor Protocol Number: RRK4368 Start Date*: 2012-11-29
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy.
    Medical condition: Transitional cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10061620 Adenocarcinoma with transitional cell carcinoma of bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002505-62 Sponsor Protocol Number: STH16404 Start Date*: 2013-11-14
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: SarCaBon: A randomised phase II trial of Saracatinib versus placebo for cancer-induced bone pain
    Medical condition: Cancer-induced bone pain
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10049038 Metastatic bone pain LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001855-12 Sponsor Protocol Number: BO 18040 Start Date*: 2004-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal ...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001854-10 Sponsor Protocol Number: BO18039 Start Date*: 2005-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004771-40 Sponsor Protocol Number: ML41742 Start Date*: 2020-04-28
    Sponsor Name:Rigshospitalet
    Full Title: ProTarget A Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling
    Medical condition: Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004984-11 Sponsor Protocol Number: P150962J Start Date*: 2018-07-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: "Study of maintenance of the efficacy and adverse effects of pharmacological treatments in sex offenders with paraphilia" ESPARA
    Medical condition: Sexual offenders with paraphilia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10033888 Paraphilia PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001539-23 Sponsor Protocol Number: PET_ONKO Start Date*: 2006-06-07
    Sponsor Name:department of clinical pharmacology
    Full Title: Does imatinib therapy lead to an increased uptake of low molecular weight substances into solid tumor metastasis in patients with hormone refractory prostate cancer?
    Medical condition: patients with HRPC and bone metastases will be enrolled in the study
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 21:34:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA